0001437749-26-013195.txt : 20260423 0001437749-26-013195.hdr.sgml : 20260423 20260423164514 ACCESSION NUMBER: 0001437749-26-013195 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20260423 ITEM INFORMATION: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20260423 DATE AS OF CHANGE: 20260423 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxart, Inc. CENTRAL INDEX KEY: 0000072444 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences EIN: 591212264 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-35285 FILM NUMBER: 26889329 BUSINESS ADDRESS: STREET 1: 310 UTAH AVENUE, SUITE 150 CITY: SOUTH SAN FRANCISCO STATE: CA BUSINESS PHONE: (650) 550-3500 MAIL ADDRESS: STREET 1: 310 UTAH AVENUE, SUITE 150 CITY: SOUTH SAN FRANCISCO STATE: CA FORMER COMPANY: FORMER CONFORMED NAME: Aviragen Therapeutics, Inc. DATE OF NAME CHANGE: 20160413 FORMER COMPANY: FORMER CONFORMED NAME: Biota Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20121113 FORMER COMPANY: FORMER CONFORMED NAME: NABI BIOPHARMACEUTICALS DATE OF NAME CHANGE: 20100719 8-K 1 vxrt20260423_8k.htm FORM 8-K vxrt20260423_8k.htm
false 0000072444 0000072444 2026-04-23 2026-04-23
 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
 
FORM 8-K
 
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934
 
Date of Report (Date of earliest event reported):
  
April 23, 2026
 
 
Vaxart, Inc.
  
 
(Exact name of registrant as specified in its charter)
  
 
 
Delaware
  
001-35285
  
59-1212264
(State or other jurisdiction of incorporation)
  
(Commission File Number)
  
(IRS Employer Identification No.)
         
310 Utah Ave, Suite 150, South San Francisco, California
  
94080
(Address of principal executive offices)
  
(Zip Code)
 
Registrant’s telephone number, including area code:
  
(650) 550-3500
 
 
170 Harbor Way, Suite 300, South San Francisco, California 94080
  
 
(Former name or former address, if changed since last report.)
  
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
 
Securities registered pursuant to Section 12(b) of the Act:
 
Title of each class
  
Trading symbol
  
Name of each exchange on which registered
Common Stock, $0.0001 par value
  
VXRT
  
*
 
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging Growth Company          ☐
 
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
 
* The registrant’s common stock is quoted on the OTCQX® Best Market under the symbol “VXRT.”
 
 
 
 
Item 5.02
  
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
 
On April 23, 2026, following a recommendation by the Nominating and Governance Committee of the Board of Directors (the “Board”) of Vaxart, Inc. (the “Company”), the Board appointed James B. Breitmeyer, M.D., Ph.D. to serve on the Board, effective immediately, and until Dr. Breitmeyer’s successor is elected and qualified, or sooner in the event of his death, resignation, or removal. The Board has determined that Dr. Breitmeyer meets the independence standards adopted by the Board.
 
James B. Breitmeyer, M.D., Ph.D. currently serves as the Chief Executive Officer and director of Altay Therapeutics, Inc. and as Operating Partner of SOLVE FSHD, a venture philanthropy group, since February 2026 and September 2025, respectively. Previously, Dr. Breitmeyer served as President and Chief Executive Officer of Oncternal Therapeutics, Inc. from February 2016 to June 2025. Dr. Breitmeyer is a veteran biotech executive with experience successfully starting and growing biotechnology organizations. He has been responsible for the development and implementation of operational and drug development strategies, as well as supervising and managing both large organizations and emerging biotechnology companies. Dr. Breitmeyer served as President of Bavarian Nordic, Inc. and Executive Vice President of Bavarian Nordic A/S, a multinational corporation headquartered in Denmark, from February 2013 to July 2015 where he oversaw business operations and development strategy both for Bavarian Nordic, Inc. and Bavarian Nordic A/S. He served as a director of Zogenix, Inc., then a public pharmaceutical company, from March 2014 until it was acquired by UCB S.A. in March 2022 and was acting Chief Medical Officer of Zogenix from August 2012 to February 2013 where he was responsible for clinical development and regulatory strategy. He previously served as the Executive Vice President of Development and Chief Medical Officer of Cadence Pharmaceuticals Inc., a public pharmaceutical company, from August 2006 to August 2012, and the Chief Medical Officer of Applied Molecular Evolution Inc., a wholly owned subsidiary of Eli Lilly and Co., a global pharmaceutical company, from December 2001 to August 2006. Dr. Breitmeyer was also the founder, President and Chief Executive Officer of the Harvard Clinical Research Institute, and Chief Medical Officer and Head of Research & Development for North America at Serono Laboratories Inc., an international biopharmaceutical company. Dr. Breitmeyer served as a founding collaborator and scientific advisor to Immunogen Inc., a biotechnology company, and held clinical and teaching positions at the Dana Farber Cancer Institute and Harvard Medical School. Dr. Breitmeyer previously served as a director of Otonomy, Inc. Dr. Breitmeyer earned his B.A. in Chemistry from the University of California, Santa Cruz and his M.D. and Ph.D. from Washington University School of Medicine and is Board Certified in Internal Medicine and Oncology. He holds an active California medical license. The Board believes that Dr. Breitmeyer’s perspective and experience as Altay’s CEO and director, as well as his depth of operating and senior management experience in the pharmaceutical industry in both private and public organizations and educational background, provide him with the qualifications and abilities to serve as a director.
 
Dr. Breitmeyer will be entitled to receive cash and equity compensation for his service on the Board and committees thereof in the standard amounts previously approved by the Board and as set forth in the Vaxart, Inc. Non-Employee Director Compensation Program.
 
Dr. Breitmeyer also entered into the Company’s standard form of indemnification agreement, the form of which is filed as Exhibit 10.3 to the Company’s Current Report on Form 8-K (File No. 001-35285), filed with the U.S. Securities and Exchange Commission on February 20, 2018.
 
There are no arrangements or understandings between Dr. Breitmeyer and any other persons, pursuant to which he was appointed as a member of the Board. There are no family relationships between Dr. Breitmeyer and any of the Company’s directors or executive officers. Dr. Breitmeyer is not a party to any current or proposed transaction with the Company for which disclosure is required under Item 404(a) of Regulation S-K.
 
Item 7.01
  
Regulation FD Disclosure.
 
On April 23, 2026, the Company issued a press release announcing the appointment of Dr. Breitmeyer as a member of the Board. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.
 
 
 
 
The information in this Item 7.01, and Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, regardless of any general incorporation language in such filing.
 
Item 9.01
  
Financial Statements and Exhibits.
 
Exhibit No.
  
Description
99.1
  
104
  
Cover Page Interactive Data File (embedded within the Inline XBRL document).
 
 
 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
Date: April 23, 2026
  
VAXART, INC.
     
   
/s/ Steven Lo
   
Steven Lo
   
President and Chief Executive Officer
 
 
 EX-99.1 2 ex_949823.htm EXHIBIT 99.1 ex_949823.htm

Exhibit 99.1

 

Vaxart Appoints James Breitmeyer, M.D., Ph.D., to Board of Directors

 

Appointment strengthens Board’s clinical development and regulatory expertise as Vaxart advances its oral vaccine platform

 

SOUTH SAN FRANCISCO, Calif., April 23, 2026 — Vaxart, Inc. (OTCQX: VXRT), a clinical-stage biotechnology company developing a range of oral vaccines based on its proprietary delivery platform, today announced the appointment of James Breitmeyer, M.D., Ph.D., to its Board of Directors. Dr. Breitmeyer brings more than 35 years of biopharmaceutical experience, having led clinical development programs resulting in eight FDA product approvals and numerous regulatory successes across the United States, Europe, and Japan.

 

"We are pleased to welcome Jim to the Vaxart Board as we continue to advance our clinical programs and demonstrate the long-term potential of our oral vaccine platform," said Mark Watson, Lead Independent Director of Vaxart. "Jim’s deep expertise in drug development and his extensive experience navigating complex regulatory paths will be a significant asset. His track record of clinical leadership is a valuable addition to our Board and is highly complementary to our mission of providing a more effective and accessible way to vaccinate the global population."

 

Dr. Breitmeyer has been a leader in drug development throughout his career. In February 2026, he joined Altay Therapeutics as CEO and Board Director, directing the advancement of the company’s pipeline of oral transcription factor therapies. He most recently served as the President and CEO of Oncternal Therapeutics, Inc., where he oversaw the clinical development of a diverse pipeline of first-in-class oncology assets. He also brings vaccine development expertise from his previous role as President of Bavarian Nordic, Inc., where he oversaw the development of cancer, infectious disease and bioterrorism vaccines. Additionally, Dr. Breitmeyer held senior clinical leadership roles at Eli Lilly and Company and Cadence Pharmaceuticals, where he managed the transition of multiple candidates through the clinical and regulatory process toward successful commercial launch.

 

"Vaxart is doing important work to advance the science of oral vaccines, and I have long admired the Company's commitment to innovation," said Dr. Breitmeyer. "I am honored to join the Board and look forward to contributing to the company's continued progress as it moves its lead candidates through the clinic and works to validate the unique advantages of its proprietary technology."

 

 
 

 

About James Breitmeyer, M.D., Ph.D.

 

Dr. Breitmeyer currently serves as the CEO and Board Director of Altay Therapeutics, Inc. His board experience includes previous director roles at Zogenix, Inc. and Otonomy, Inc., where he served on Audit and Compensation Committees.

 

Prior to joining Altay Therapeutics, he most recently served as President, CEO, and Director of Oncternal Therapeutics, Inc. Previously, he held the position of President at Bavarian Nordic, Inc. and served as Executive Vice President and Chief Medical Officer at Cadence Pharmaceuticals. Dr. Breitmeyer also served as Vice President of Biotechnology at Eli Lilly and Company, where he was responsible for the corporate biotechnology pipeline. Earlier in his career, he held senior leadership roles at Applied Molecular Evolution and Serono Laboratories, where he led the development of therapies resulting in FDA approvals for Rebif® and Serostim®.

 

Dr. Breitmeyer earned his M.D. and Ph.D. from Washington University School of Medicine. He completed postdoctoral fellowships at Harvard Medical School and the Dana-Farber Cancer Institute, where he also served as a clinical instructor.

 

About Vaxart

 

Vaxart is a clinical-stage biotechnology company developing a range of oral recombinant vaccines based on its proprietary delivery platform. Vaxart vaccines are designed to be administered using pills that can be stored and shipped without refrigeration and eliminate the risk of needle-stick injury. Vaxart believes that its proprietary pill vaccine delivery platform is suitable to deliver recombinant vaccines, positioning the company to develop oral versions of currently marketed vaccines and to design recombinant vaccines for new indications. Vaxart’s development programs currently include pill vaccines designed to protect against coronavirus, norovirus and influenza, as well as a therapeutic vaccine for human papillomavirus (HPV), Vaxart’s first immune-oncology indication. Vaxart has filed broad domestic and international patent applications covering its proprietary technology and creations for oral vaccination using adenovirus and TLR3 agonists.

 

 
 

 

Note Regarding Forward-Looking Statements

 

This press release contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, included in this press release regarding Vaxart's strategy, prospects, plans and objectives, results from preclinical and clinical trials and the timing of such results, and beliefs and expectations of management are forward-looking statements. These forward-looking statements may be accompanied by such words as "should," "believe," "could," "potential," "will," "expected," “anticipate,” "plan," and other words and terms of similar meaning. Examples of such statements include, but are not limited to, statements relating to Vaxart's ability to develop and commercialize its product candidates; Vaxart's expectations regarding clinical results and trial data, and the timing of receiving and reporting such clinical results and trial data; Vaxart’s expected timing for future clinical trials; and Vaxart's expectations with respect to the effectiveness of its product candidates. Vaxart may not actually achieve the plans, carry out the intentions, or meet the expectations or projections disclosed in the forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions, expectations, and projections disclosed in the forward-looking statements. Various important factors could cause actual results or events to differ materially from the forward-looking statements that Vaxart makes, including uncertainties inherent in research and development, including the ability to meet anticipated clinical endpoints, commencement, and/or completion dates for clinical trials, as well as the possibility of unfavorable new clinical data and further analyses of existing clinical data; the risk that clinical trial data are subject to differing interpretations and assessments by regulatory authorities; whether regulatory authorities will be satisfied with the design of and results from the clinical studies; decisions by regulatory authorities impacting labeling, manufacturing processes, and safety that could affect the availability or commercial potential of any product candidate, including the possibility that Vaxart's product candidates may not be approved by the FDA or non-U.S. regulatory authorities; that Vaxart or its partners may experience manufacturing issues and delays due to events within, or outside of, Vaxart's or its partners' control; Vaxart's ability to obtain sufficient capital to fund its operations on terms acceptable to Vaxart, if at all; the impact of government healthcare proposals and policies; competitive factors; and other risks described in the "Risk Factors" sections of Vaxart's Quarterly and Annual Reports filed with the SEC. Vaxart does not assume any obligation to update any forward-looking statements, except as required by law.

 

Contact

Vaxart Media and Investor Relations:

FINN Partners

IR@vaxart.com

 

 
 EX-101.SCH 3 vxrt-20260423.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 vxrt-20260423_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 vxrt-20260423_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security Trading Symbol Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 vxrt-20260423_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 8 R1.htm IDEA: XBRL DOCUMENT v3.26.1
Document And Entity Information
Apr. 23, 2026
Document Information [Line Items]  
Entity, Registrant Name Vaxart, Inc.
Document, Type 8-K
Document, Period End Date Apr. 23, 2026
Entity, Incorporation, State or Country Code DE
Entity, File Number 001-35285
Entity, Tax Identification Number 59-1212264
Entity, Address, Address Line One 310 Utah Ave, Suite 150
Entity, Address, City or Town South San Francisco
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 94080
City Area Code 650
Local Phone Number 550-3500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock
Trading Symbol VXRT
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000072444
XML 9 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ .report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } .report table.authRefData a { display: block; font-weight: bold; } .report table.authRefData p { margin-top: 0px; } .report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } .report table.authRefData .hide a:hover { background-color: #2F4497; } .report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } .report table.authRefData table{ font-size: 1em; } /* Report Styles */ .pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ .report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } .report hr { border: 1px solid #acf; } /* Top labels */ .report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } .report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } .report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } .report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } .report td.pl div.a { width: 200px; } .report td.pl a:hover { background-color: #ffc; } /* Header rows... */ .report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ .report .rc { background-color: #f0f0f0; } /* Even rows... */ .report .re, .report .reu { background-color: #def; } .report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ .report .ro, .report .rou { background-color: white; } .report .rou td { border-bottom: 1px solid black; } .report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ .report .fn { white-space: nowrap; } /* styles for numeric types */ .report .num, .report .nump { text-align: right; white-space: nowrap; } .report .nump { padding-left: 2em; } .report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ .report .text { text-align: left; white-space: normal; } .report .text .big { margin-bottom: 1em; width: 17em; } .report .text .more { display: none; } .report .text .note { font-style: italic; font-weight: bold; } .report .text .small { width: 10em; } .report sup { font-style: italic; } .report .outerFootnotes { font-size: 1em; } XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.26.1 html 1 21 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.vxrt.com/20260423/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports vxrt-20260423.xsd vxrt-20260423_def.xml vxrt-20260423_lab.xml vxrt-20260423_pre.xml vxrt20260423_8k.htm http://xbrl.sec.gov/dei/2024 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "vxrt20260423_8k.htm": { "nsprefix": "vxrt", "nsuri": "http://www.vxrt.com/20260423", "dts": { "schema": { "local": [ "vxrt-20260423.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.sec.gov/country/2024/country-2024.xsd", "https://xbrl.sec.gov/currency/2024/currency-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-8k-sub-2024.xsd", "https://xbrl.sec.gov/cyd/2024/cyd-cr-2024.xsd", "https://xbrl.sec.gov/dei/2024/dei-2024.xsd", "https://xbrl.sec.gov/exch/2024/exch-2024.xsd", "https://xbrl.sec.gov/sic/2024/sic-2024.xsd", "https://xbrl.sec.gov/stpr/2024/stpr-2024.xsd" ] }, "definitionLink": { "local": [ "vxrt-20260423_def.xml" ] }, "labelLink": { "local": [ "vxrt-20260423_lab.xml" ] }, "presentationLink": { "local": [ "vxrt-20260423_pre.xml" ] }, "inline": { "local": [ "vxrt20260423_8k.htm" ] } }, "keyStandard": 21, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2024": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 35, "unitCount": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2024": 21 }, "report": { "R1": { "role": "http://www.vxrt.com/20260423/role/statement-document-and-entity-information", "longName": "000 - Document - Document And Entity Information", "shortName": "Document And Entity Information", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "d20268K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "vxrt20260423_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "d20268K", "name": "dei:EntityRegistrantName", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "b", "div", "td", "tr", "tbody", "table", "body", "html" ], "reportCount": 1, "baseRef": "vxrt20260423_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "AmendmentFlag", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "CityAreaCode", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentInformationLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationLineItems", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document Information [Line Items]", "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table." } } }, "auth_ref": [] }, "dei_DocumentInformationTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentInformationTable", "lang": { "en-us": { "role": { "label": "Document Information [Table]", "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentPeriodEndDate", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "DocumentType", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Document, Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressAddressLine1", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressCityOrTown", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityCentralIndexKey", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r1" ] }, "dei_EntityDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityDomain", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity [Domain]", "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r1" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityFileNumber", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityRegistrantName", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r1" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Entity, Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r1" ] }, "dei_LegalEntityAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LegalEntityAxis", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Legal Entity [Axis]", "documentation": "The set of legal entities associated with a report." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "LocalPhoneNumber", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "cyd_MaterialCybersecurityIncidentAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentAbstract", "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Abstract]" } } }, "auth_ref": [ "r5", "r6" ] }, "cyd_MaterialCybersecurityIncidentAxis": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentAxis", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Axis]" } } }, "auth_ref": [ "r5", "r6" ] }, "cyd_MaterialCybersecurityIncidentDomain": { "xbrltype": "domainItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentDomain", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Domain]" } } }, "auth_ref": [ "r5", "r6" ] }, "cyd_MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentInformationNotAvailableOrUndeterminedTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Information Not Available or Undetermined [Text Block]" } } }, "auth_ref": [ "r5", "r7" ] }, "cyd_MaterialCybersecurityIncidentLineItems": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentLineItems", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Line Items]" } } }, "auth_ref": [ "r5", "r8" ] }, "cyd_MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentMaterialImpactOrReasonablyLikelyMaterialImpactTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Material Impact or Reasonably Likely Material Impact [Text Block]" } } }, "auth_ref": [ "r5", "r8" ] }, "cyd_MaterialCybersecurityIncidentNatureTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentNatureTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Nature [Text Block]" } } }, "auth_ref": [ "r5", "r8" ] }, "cyd_MaterialCybersecurityIncidentScopeTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentScopeTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Scope [Text Block]" } } }, "auth_ref": [ "r5", "r8" ] }, "cyd_MaterialCybersecurityIncidentTable": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentTable", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident [Table]" } } }, "auth_ref": [ "r5", "r6" ] }, "cyd_MaterialCybersecurityIncidentTimingTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/cyd/2024", "localname": "MaterialCybersecurityIncidentTimingTextBlock", "presentation": [ "http://xbrl.sec.gov/cyd/role/MaterialCybersecurityIncidentDisclosure" ], "lang": { "en-us": { "role": { "label": "Material Cybersecurity Incident Timing [Text Block]" } } }, "auth_ref": [ "r5", "r8" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "PreCommencementTenderOffer", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r4" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "Security12bTitle", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r0" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "SolicitingMaterial", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r3" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "TradingSymbol", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2024", "localname": "WrittenCommunications", "presentation": [ "http://www.vxrt.com/20260423/role/statement-document-and-entity-information" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r9" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14a", "Subsection": "12" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 6-K", "Section": "General Instruction", "Subsection": "B" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "Instruction", "Paragraph": "2" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 8-K", "Section": "1.05", "Subsection": "a" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" } } } ZIP 15 0001437749-26-013195-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-26-013195-xbrl.zip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vxrt20260423_8k_htm.xml IDEA: XBRL DOCUMENT 0000072444 2026-04-23 2026-04-23 false 0000072444 8-K 2026-04-23 Vaxart, Inc. DE 001-35285 59-1212264 310 Utah Ave, Suite 150 South San Francisco CA 94080 650 550-3500 false false false false Common Stock VXRT false